References
- Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019 May;94(S1):S3-9. DOI: 10.1002/ajh.25418
- Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N Engl J Med. 2021 Aug 5;385(6):567-9. DOI: 10.1056/NEJMc2107725
- Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020 Mar;17(3):147-67. DOI: 10.1038/s41571-019-0297-y
- Jensen MC, Riddell SR. Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol. 2015 Apr;33:9-15. DOI: 10.1016/j.coi.2015.01.002
- Fujiwara K, Tsunei A, Kusabuka H, Ogaki E, Tachibana M, Okada N. Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold. Cells. 2020 May 9;9(5):1182. DOI: 10.3390/cells9051182
- Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014 Jan;257(1):107-26. DOI: 10.1111/imr.12131
- Gerdemann U, Christin AS, Vera JF, Ramos CA, Fujita Y, Liu H, et al. Nucleofection of DCs to Generate Multivirus-specific T Cells for Prevention or Treatment of Viral Infections in the Immunocompromised Host. Mol Ther. 2009 Sep 1;17(9):1616-25. DOI: 10.1038/mt.2009.140
- FDA approves axicabtagene ciloleucel for large B-cell lymphoma. FDA [Internet]. 2019 Feb 9 [cited 2023 Apr 19]; Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-axicabtagene-ciloleucel-large-b-cell-lymphoma
- FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome. FDA [Internet]. 2019 Feb 9 [cited 2023 Apr 19]; Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisagenlecleucel-b-cell-all-and-tocilizumab-cytokine-release-syndrome
- Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering. Nature. 2017 May;545(7655):423-31. DOI: 10.1038/nature22395
- Kawalekar OU, O’Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, et al. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity. 2016 Feb 16;44(2):380-90. DOI: 10.1016/j. immuni.2016.01.021
- Philipson BI, O’Connor RS, May MJ, June CH, Albelda SM, Milone MC. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling. Sci Signal. 2020 Mar 31;13(625):eaay8248. DOI: 10.1126/scisignal.aay8248
- Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020 Nov 10;4(21):5414-24. DOI: 10.1182/bloodadvances.2020003092
- Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol. 2012 Feb 17;12(3):191-200. DOI: 10.1038/nri3158
- Miltenyi Biotec. CD19 CAR Detection Reagent Protocol [Internet]. Available from: https://www.miltenyibiotec.com/upload/assets/IM0028385.PDF
- BD Biosciences. BD Biosciences TBNK Instructions For Use [Internet]. Available from: https://www.bdbiosciences.com/content/dam/bdb/products/global/reagents/flow-cytometryreagents/clinical-diagnostics/multicolor-cocktails-and-kits-ivdce-ivds/662967_base/pdf/23-19817.pdf
- Demaret J, Varlet P, Trauet J, Beauvais D, Grossemy A, Hégo F, et al. Monitoring CAR T-cells using flow cytometry. Cytometry B Clin Cytom. 2021 Mar;100(2):218-24. DOI: 10.1002/cyto.b.21941
- Peinelt A, Bremm M, Kreyenberg H, Cappel C, Banisharif-Dehkordi J, Erben S, et al. Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following Tisagenlecleucel. Front Immunol. 2022;13:830773. DOI: 10.3389/fimmu.2022.830773
- Blache U, Weiss R, Boldt A, Kapinsky M, Blaudszun AR, Quaiser A, et al. Advanced Flow Cytometry Assays for Immune Monitoring of CAR T Cell Applications. Front Immunol [Internet]. 2021 [cited 2023 Apr 19];12. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2021.658314 DOI: 10.3389/fimmu.2021.658314
- Kochenderfer JN, Somerville RPT, Lu T, Yang JC, Sherry RM, Feldman SA, et al. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. Mol Ther J Am Soc Gene Ther. 2017 Oct 4;25(10):2245-53. DOI: 10.1016/j.ymthe.2017.07.004
- Liu Q, Sun Z, Chen L. Memory T cells: strategies for optimizing tumor immunotherapy. Protein Cell. 2020 Aug;11(8):549-64. DOI: 10.1007/s13238-020-00707-9
- Busch DH, Fräßle SP, Sommermeyer D, Buchholz VR, Riddell SR. Role of memory T cell subsets for adoptive immunotherapy. Semin Immunol. 2016 Feb;28(1):28-34. DOI: 10.1016/j. smim.2016.02.001
- Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018 Oct;24(10):1499-1503. DOI: 10.1038/s41591-018-0201-9
- Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med. 2014 Oct 16;371(16):1507-17. DOI: 10.1056/NEJMoa1407222